Oxaliplatin derived monofunctional triazole-containing platinum(II) complex counteracts oxaliplatin-induced drug resistance in colorectal cancer

Yaru Li,Ziru Sun,Yujun Cui,Heming Zhang,Shunjie Zhang,Xinyu Wang,Shengnan Liu,Qingzhi Gao

DOI: https://doi.org/10.1016/j.bioorg.2021.104636

IF: 5.307

2021-02-01

Bioorganic Chemistry

Abstract:<p>Oxaliplatin-based chemotherapy is the current standard of care in adjuvant therapy for advanced colorectal cancer (CRC). But acquired resistance to oxaliplatin eventually occurs and becoming a major cause of treatment failure. Thus, there is an unmet need for developing new chemical entities (NCE) as new therapeutic candidates to target chemotherapy-resistant CRC. Novel Pt(II) complexes were designed and synthesized as cationic monofunctional oxaliplatin derivatives for DNA platination-mediated tumor targeting. The complex Ph-glu-Oxa sharing the same chelating ligand of diaminocyclohexane (DACH) with oxaliplatin but is equally potent in inhibiting the proliferation of HT29 colon cancer cells and its oxaliplatin-resistant phenotype of HT29/Oxa. The <em>in vivo</em> therapeutic potential of Ph-glu-Oxa was confirmed in oxaliplatin-resistant xenograft model demonstrating the reversibility of the drug resistance by the new complex and the efficacy was associated with the unimpaired high intracellular drug accumulation in HT29/Oxa. Guanosine-5'-monophosphate (5'-GMP) reactivity, double-strand plasmid DNA cleavage, DNA-intercalated ethidium bromide (EB) fluorescence quenching and atomic force microscopy (AFM)-mediated DNA denaturing studies revealed that Ph-glu-Oxa was intrinsically active as DNA-targeting agent. The diminished susceptibility of the complex to glutathione (GSH)-mediated detoxification, which confers high intracellular accumulation of the drug molecule may play a key role in maintaining cytotoxicity and counteracting oxaliplatin drug resistance.</p>

biochemistry & molecular biology,chemistry, organic

What problem does this paper attempt to address?

The main problem this paper attempts to address is overcoming the resistance of colorectal cancer (CRC) to oxaliplatin. Oxaliplatin is currently the standard adjuvant chemotherapy drug for treating advanced colorectal cancer, but patients eventually develop acquired resistance to this drug, which becomes the primary cause of treatment failure. Therefore, there is a significant clinical need to develop new chemical entities (NCEs) as new candidate drugs for treating resistant colorectal cancer.

To tackle this challenge, researchers designed and synthesized new platinum(II) complexes, which are monofunctional derivatives of oxaliplatin, aimed at achieving tumor targeting through DNA platination. Specifically, a complex named Ph-glu-Oxa synthesized in the study showed comparable efficacy to oxaliplatin in inhibiting the proliferation of HT29 colorectal cancer cells and their oxaliplatin-resistant phenotype HT29/Oxa cells. Additionally, Ph-glu-Oxa demonstrated the potential to reverse oxaliplatin resistance in in vivo experiments, and its efficacy was associated with the high intracellular drug accumulation in HT29/Oxa cells that remained unaffected.

The study also found that Ph-glu-Oxa exhibited reduced sensitivity to glutathione (GSH)-mediated detoxification, which may be a key factor in maintaining cytotoxicity and combating oxaliplatin drug resistance. In summary, this research aims to address the issue of oxaliplatin resistance in colorectal cancer treatment by designing novel platinum(II) complexes, thereby improving therapeutic outcomes.